TAAR1: the metabolic target after GLP-1
A 2026 pharmacology review argues TAAR1 can replicate GLP-1 agonist effects through a distinct receptor, with additional action on brain reward circuits.
Why we wrote this. A 2026 peer-reviewed review positions TAAR1 as a serious next-generation metabolic target. Readers in the semaglutide cluster need this context before vendor channels amplify it.
In this article (5 sections)
A review chapter published in the Handbook of Experimental Pharmacology on 11 July 2026 argues that trace amine-associated receptor 1 (TAAR1) deserves attention as a metabolic drug target, one with significant mechanistic overlap with semaglutide and the GLP-1 class but acting through a distinct receptor[1]. The authors, Lenham, Elgammal, Harding and Berry, are not announcing an approved medicine. They are making a mechanistic case for a next-generation target.
What is TAAR1?
TAAR1 is a G-protein coupled receptor found in pancreatic beta-cells, the gut, and appetite-regulating regions of the brain. Its natural ligands are trace amines, low-concentration compounds structurally related to catecholamines. Raab and colleagues demonstrated in 2015 that a selective small-molecule TAAR1 agonist increased glucose-dependent insulin secretion in INS1E cells and human islets, and elevated plasma GLP-1 and PYY in mice[2]. That paper established the phrase "incretin-like" for TAAR1 activation, and the 2026 Lenham review builds on it.
The signal path in beta-cells runs through cAMP-dependent protein kinase A, the same second-messenger cascade GLP-1 receptor agonists use. Michael, Covic and Kuliopulos characterised this pathway in human insulin-secreting cells in 2019, finding that TAAR1 activation also drives CREB phosphorylation and downstream expression of IRS-2, a gene that supports beta-cell survival[3].
How TAAR1 compares to the GLP-1 pathway
The mechanistic overlap with GLP-1 receptor agonists is real: both increase glucose-dependent insulin secretion and reduce food intake. The Lenham review notes a distinction in where the central action sits. TAAR1 is expressed in homeostatic and hedonic feeding centres in the brain independently of peripheral GLP-1 release. Dedic and colleagues confirmed in a 2024 Molecular Metabolism study that three TAAR1 agonists, including ulotaront, reduced body weight, food intake, and liver triglycerides in obese animal models by acting on both peripheral and central circuits[4].
The review also notes that TAAR1 sits at the intersection of metabolic control and dopaminergic reward signalling, the circuits involved in compulsive eating and food-related habit formation. The 2026 authors argue this dual action means TAAR1 compounds could address behavioural aspects of metabolic disease that GLP-1 receptor agonists reach only indirectly.
The clinical picture as of mid-2026
Ulotaront (SEP-363856), originally developed for schizophrenia, is the TAAR1 agonist with the most human metabolic data. A 2026 open-label study by Milanovic and colleagues in Diabetes, Obesity and Metabolism enrolled schizophrenia patients with metabolic syndrome and prediabetes, a population that often experiences worsened glucose handling as a side effect of antipsychotic treatment. The researchers reported reductions in glucose area under the curve during oral glucose tolerance testing and a statistically significant reduction in insulin response during a mixed meal tolerance test (p = 0.021)[1]. The sample was small and the design was open-label: this is signal-generating, not confirmatory evidence. The authors acknowledged the limited sample size explicitly.
No TAAR1 agonist is approved for type-2 diabetes or obesity by any agency. For a sense of what regulatory approval looks like in this therapeutic space, the semaglutide page covers the evidence base and the per-country authorisation status for Ozempic, Rybelsus and Wegovy.
What we do not know yet
The Lenham review is direct about the gaps. Most mechanistic work is in rodents or cell lines. The human pharmacokinetics and safety of TAAR1 agonists in a purely metabolic population, without concurrent psychiatric comorbidity, have not been characterised. There is no Phase 2 or Phase 3 trial specifically designed around glucose control or weight loss as primary endpoints in people without a psychiatric indication. The role of TAAR1 in human brown adipose tissue thermogenesis, mentioned in the review as a possible third metabolic lever, is speculative. Whether TAAR1 agonism produces less gastric-emptying delay than the GLP-1 class (and therefore fewer gastrointestinal adverse events) has not been tested at scale in humans.
Where this lands
The 2026 Handbook chapter is a mechanistic argument, not a clinical directive. It positions TAAR1 as a target worth building drug programmes around, using GLP-1 receptor agonist biology as the benchmark. Whether any TAAR1-selective compound clears Phase 3 efficacy and safety requirements for metabolic disease is a question for trials that have not yet been designed.
Readers following the incretin field after the first generation of GLP-1 medicines will find the mechanistic framing in this review useful as a map of where the next receptor-target conversation is headed. The place to watch for confirmatory signals is the peer-reviewed trial registry, not vendor channels, which have a consistent track record of getting ahead of the data on emerging targets.
Frequently asked
What is TAAR1 and why does it matter for diabetes and obesity?
TAAR1 (trace amine-associated receptor 1) is a G-protein coupled receptor found in pancreatic beta-cells, the gut, and appetite-regulating brain regions. Activating it increases glucose-dependent insulin secretion and reduces food intake through both peripheral and central mechanisms. Researchers are interested in it as a drug target for type-2 diabetes and obesity because it overlaps mechanistically with GLP-1 receptor agonists while also acting on dopaminergic reward circuits involved in compulsive eating.
Is TAAR1 the same as a GLP-1 receptor agonist?
No. They are distinct receptors with overlapping downstream effects. GLP-1 receptor agonists like semaglutide bind the GLP-1 receptor. TAAR1 agonists bind a separate receptor expressed in overlapping metabolic tissues and also in brain regions the GLP-1 class does not primarily target. The 2026 Lenham review argues the overlap is significant but the two targets are not interchangeable.
Is any TAAR1 drug approved for obesity or diabetes?
No. As of mid-2026, no TAAR1 agonist is approved by the FDA, EMA, MHRA, or any national agency for type-2 diabetes or obesity. Ulotaront (SEP-363856) has been studied in small metabolic-focused trials as part of psychiatric drug development, but there is no Phase 3 programme targeting diabetes or obesity as primary endpoints.
How does TAAR1 research relate to semaglutide?
The Lenham et al. (2026) review uses GLP-1 receptor agonists, including semaglutide, as the comparison framework. TAAR1 activation drives some of the same downstream effects (glucose-dependent insulin secretion, reduced appetite) while also engaging brain reward circuits the GLP-1 class reaches less directly. The review positions TAAR1 as a potential next-generation target, not a replacement for existing approved medicines.
Sources
- [1]Lenham RK et al. TAAR1 as a Potential Alternate Molecular Target to GLP-1 for Novel Anti-diabetic, Anti-obesity Medications. Handbook of Experimental Pharmacology, 2026. PMID 42432129Tier 1 · primary↩
- [2]Raab S et al. Incretin-like effects of small molecule trace amine-associated receptor 1 agonists. Molecular Metabolism, 2015. PMID 26844206Tier 1 · primary↩
- [3]Michael ES, Covic L, Kuliopulos A. Trace amine-associated receptor 1 promotes anti-diabetic signaling in insulin-secreting cells. Journal of Biological Chemistry, 2019. PMID 30670596Tier 1 · primary↩
- [4]Dedic N et al. TAAR1 agonists improve glycemic control, reduce body weight and modulate neurocircuits governing energy balance and feeding. Molecular Metabolism, 2024. PMID 38237896Tier 1 · primary↩
No revisions yet. First published .